123 related articles for article (PubMed ID: 35146945)
1. A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease.
Pennisi G; Pipitone RM; Enea M; De Vincentis A; Battaglia S; Di Marco V; Di Martino V; Spatola F; Tavaglione F; Vespasiani-Gentilucci U; Zito R; Romeo S; Cammà C; Craxì A; Grimaudo S; Petta S
Hepatol Commun; 2022 May; 6(5):1032-1044. PubMed ID: 35146945
[TBL] [Abstract][Full Text] [Related]
2. The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD.
Kamada Y; Munekage K; Nakahara T; Fujii H; Sawai Y; Doi Y; Hyogo H; Sumida Y; Imai Y; Miyoshi E; Ono M;
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615725
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
5. Predicting liver-related events in NAFLD: A predictive model.
Calzadilla-Bertot L; Jeffrey GP; Wang Z; Huang Y; Garas G; Wallace M; de Boer B; George J; Eslam M; Phu A; Ampuero J; Lucena Valera A; Romero-Gómez M; Aller de la Fuente R; Adams LA
Hepatology; 2023 Oct; 78(4):1240-1251. PubMed ID: 36994693
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
Ishiba H; Sumida Y; Kamada Y; Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Takahashi H; Ueda S; Aishima S; Nakajima A; Okanoue T;
J Gastroenterol Hepatol; 2023 Jun; 38(6):896-904. PubMed ID: 36797989
[TBL] [Abstract][Full Text] [Related]
7. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
[TBL] [Abstract][Full Text] [Related]
8. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
9. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
Angulo P; Bugianesi E; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Barrera F; Haflidadottir S; Day CP; George J
Gastroenterology; 2013 Oct; 145(4):782-9.e4. PubMed ID: 23860502
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.
Berenguer J; Zamora FX; Aldámiz-Echevarría T; Von Wichmann MA; Crespo M; López-Aldeguer J; Carrero A; Montes M; Quereda C; Téllez MJ; Galindo MJ; Sanz J; Santos I; Guardiola JM; Barros C; Ortega E; Pulido F; Rubio R; Mallolas J; Tural C; Jusdado JJ; Pérez G; Díez C; Álvarez-Pellicer J; Esteban H; Bellón JM; González-García J;
Clin Infect Dis; 2015 Mar; 60(6):950-8. PubMed ID: 25422386
[TBL] [Abstract][Full Text] [Related]
11. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
Calzadilla-Bertot L; Vilar-Gomez E; Wong VW; Romero-Gomez M; Aller-de la Fuente R; Wong GL; Castellanos M; Eslam M; Desai AP; Jeffrey GP; George J; Chalasani N; Adams LA
Hepatology; 2021 Jun; 73(6):2238-2250. PubMed ID: 32978796
[TBL] [Abstract][Full Text] [Related]
12. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
13. Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents.
Hsu WF; Lai HC; Chuang PH; Su WP; Chen SH; Chen HY; Wang HW; Huang GT; Peng CY
J Viral Hepat; 2022 Sep; 29(9):785-794. PubMed ID: 35657121
[TBL] [Abstract][Full Text] [Related]
14. Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Azuma S; Asahina Y; Kakinuma S; Azuma K; Miyoshi M; Inoue E; Tsunoda T; Sato A; Kaneko S; Nagata H; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Tomita M; Nakagawa M; Watanabe M
Dig Dis; 2019; 37(3):247-254. PubMed ID: 30625487
[TBL] [Abstract][Full Text] [Related]
15. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores.
De Vincentis A; Tavaglione F; Jamialahmadi O; Picardi A; Antonelli Incalzi R; Valenti L; Romeo S; Vespasiani-Gentilucci U
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):658-673. PubMed ID: 34091049
[TBL] [Abstract][Full Text] [Related]
16. Quantification of liver extracellular volume using dual-energy CT: utility for prediction of liver-related events in cirrhosis.
Bak S; Kim JE; Bae K; Cho JM; Choi HC; Park MJ; Choi HY; Shin HS; Lee SM; Kim HO
Eur Radiol; 2020 Oct; 30(10):5317-5326. PubMed ID: 32335746
[TBL] [Abstract][Full Text] [Related]
17. Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age.
Miller MJ; Harding-Theobald E; DiBattista JV; Zhao Z; Wijarnpreecha K; Lok AS; Chen VL
Hepatol Commun; 2023 Jun; 7(6):. PubMed ID: 37267221
[TBL] [Abstract][Full Text] [Related]
18. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
Chen J; Song S; Li X; Bian D; Wu X
Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
[TBL] [Abstract][Full Text] [Related]
19. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Nishimura D; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol Hepatol; 2019 Jan; 34(1):207-214. PubMed ID: 30144360
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
